123 related articles for article (PubMed ID: 10405512)
41. Child, parent, and service predictors of psychotropic polypharmacy among adolescents and young adults with an autism spectrum disorder.
Lake JK; Weiss JA; Dergal J; Lunsky Y
J Child Adolesc Psychopharmacol; 2014 Nov; 24(9):486-93. PubMed ID: 25329798
[TBL] [Abstract][Full Text] [Related]
42. A naturalistic retrospective analysis of psychostimulants in pervasive developmental disorders.
Stigler KA; Desmond LA; Posey DJ; Wiegand RE; McDougle CJ
J Child Adolesc Psychopharmacol; 2004; 14(1):49-56. PubMed ID: 15142391
[TBL] [Abstract][Full Text] [Related]
43. Prescription trends in children with pervasive developmental disorders: a claims data-based study in Japan.
Satoh M; Obara T; Nishigori H; Ooba N; Morikawa Y; Ishikuro M; Metoki H; Kikuya M; Mano N
World J Pediatr; 2016 Nov; 12(4):443-449. PubMed ID: 27286689
[TBL] [Abstract][Full Text] [Related]
44. Imipramine and Asperger's.
Szabo CP; Bracken C
J Am Acad Child Adolesc Psychiatry; 1994; 33(3):431-2. PubMed ID: 8169195
[No Abstract] [Full Text] [Related]
45. Cognitive-adaptive disabilities.
Calles JL
Pediatr Clin North Am; 2011 Feb; 58(1):189-203, xii. PubMed ID: 21281856
[TBL] [Abstract][Full Text] [Related]
46. Psychotropic medication use in children with autism in the Kentucky Medicaid population.
Williams PG; Woods C; Stevenson M; Davis DW; Radmacher P; Smith M
Clin Pediatr (Phila); 2012 Oct; 51(10):923-7. PubMed ID: 22492834
[TBL] [Abstract][Full Text] [Related]
47. Treatment incidence and patterns in children and adolescents with autism spectrum disorders.
Witwer A; Lecavalier L
J Child Adolesc Psychopharmacol; 2005 Aug; 15(4):671-81. PubMed ID: 16190798
[TBL] [Abstract][Full Text] [Related]
48. Emerging drugs for the treatment of symptoms associated with autism spectrum disorders.
Wink LK; Plawecki MH; Erickson CA; Stigler KA; McDougle CJ
Expert Opin Emerg Drugs; 2010 Sep; 15(3):481-94. PubMed ID: 20470188
[TBL] [Abstract][Full Text] [Related]
49. Prevalence and patterns of use of psychoactive medicines in individuals with autism in the Autism Society of North Carolina.
Langworthy-Lam KS; Aman MG; Van Bourgondien ME
J Child Adolesc Psychopharmacol; 2002; 12(4):311-21. PubMed ID: 12625991
[TBL] [Abstract][Full Text] [Related]
50. Prevalence and patterns of use of psychoactive medicines among individuals with autism in the Autism Society of Ohio.
Aman MG; Lam KS; Collier-Crespin A
J Autism Dev Disord; 2003 Oct; 33(5):527-34. PubMed ID: 14594332
[TBL] [Abstract][Full Text] [Related]
51. Pharmacotherapy of target symptoms in autistic spectrum disorders.
Santosh PJ; Baird G
Indian J Pediatr; 2001 May; 68(5):427-31. PubMed ID: 11407159
[TBL] [Abstract][Full Text] [Related]
52. Buspirone for bruxism in a child with pervasive developmental disorder-not otherwise specified.
Orsagh-Yentis DK; Wink LK; Stigler KA; Erickson CA; McDougle CJ
J Child Adolesc Psychopharmacol; 2011 Dec; 21(6):643-5. PubMed ID: 22136097
[No Abstract] [Full Text] [Related]
53. Should clinical trial research of psychotropic medication in autism control for gastrointestinal symptoms?
Heitzer AM; Job MA; Pandit NK; Valdovinos MG
J Clin Pharmacol; 2014 Oct; 54(10):1093-6. PubMed ID: 24788353
[TBL] [Abstract][Full Text] [Related]
54. Prevalence and Predictors of Psychotropic Use in Children with High-Functioning ASDs.
Lopata C; Toomey JA; Fox JD; Thomeer ML; Volker MA; Lee GK
Autism Res Treat; 2013; 2013():384527. PubMed ID: 23762550
[TBL] [Abstract][Full Text] [Related]
55. Lessons from secretin.
Volkmar FR
N Engl J Med; 1999 Dec; 341(24):1842-4. PubMed ID: 10588973
[No Abstract] [Full Text] [Related]
56. What Have Proteomic Studies Taught Us About Novel Drug Targets in Autism?
Guest PC; Martins-de-Souza D
Adv Exp Med Biol; 2017; 974():49-67. PubMed ID: 28353224
[TBL] [Abstract][Full Text] [Related]
57. Asperger's syndrome.
Burd L; Kerbesharn J
Br J Psychiatry; 1987 Sep; 151():417. PubMed ID: 3427303
[No Abstract] [Full Text] [Related]
58. Pharmacologic treatment of autism and related disorders.
Erickson CA; Posey DJ; Stigler KA; McDougle CJ
Pediatr Ann; 2007 Sep; 36(9):575-85. PubMed ID: 17910205
[No Abstract] [Full Text] [Related]
59. Multidimensionally impaired disorder.
Fitzgerald M
J Am Acad Child Adolesc Psychiatry; 1998 Nov; 37(11):1125-6. PubMed ID: 9808915
[No Abstract] [Full Text] [Related]
60. Use of stimulant medication in treating pervasive developmental disorder.
Sporn A; Pinsker H
Am J Psychiatry; 1981 Jul; 138(7):997. PubMed ID: 7258372
[No Abstract] [Full Text] [Related]
[Previous] [Next] [New Search]
